Working… Menu

Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02945631
Recruitment Status : Recruiting
First Posted : October 26, 2016
Last Update Posted : September 3, 2020
Information provided by (Responsible Party):
Marshall Posner, Icahn School of Medicine at Mount Sinai

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2023
Forastiere A, Maor M, Weber R, Pajak, T, Glisson B, Trotti A, Ridge J, et al. Long term results of Intergroup RTOG 91-11: A Phase III trial to preserve the larynx - Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proceedings of the American Society of Clinical Oncology. 2006:5517.